(Q36206897)

12 August 2017

title

The impact of endpoint measures in rheumatoid arthritis clinical trials (English)

1 reference

12 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1604325

Anesthesiology and pain medicine

13 October 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

13 October 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

13 October 2022

author name string

van der Heide A

1

1 reference

12 August 2017

A. van der Heide

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1604325

13 October 2022

J. W. Jacobs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1604325

13 October 2022

H. J. Dinant

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1604325

13 October 2022

J. W. Bijlsma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1604325

13 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1604325

13 October 2022

publication date

1 April 1992

1 reference

full work available at URL

12 August 2017

https://api.elsevier.com/content/article/PII:0049017292900226?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

https://api.elsevier.com/content/article/PII:0049017292900226?httpAccept=text/plain

13 October 2022

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Seminars in Arthritis and Rheumatism

13 October 2022

published in

1 reference

12 August 2017

volume

21

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

287-294

1 reference

Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials.

12 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score

13 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

13 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis.

13 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

The assessment of disease activity in rheumatoid arthritis using a multivariate analysis

13 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Measurement of patient outcome in arthritis

13 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Measuring health status in arthritis. The arthritis impact measurement scales.

13 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures

13 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

13 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study

13 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial

13 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate

13 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis

13 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis

13 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis

13 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis--a comparative study

13 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial

13 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study

13 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine

13 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Auranofin or D-penicillamine in the treatment of rheumatoid arthritis

13 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments.

13 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation

13 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine

13 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens

13 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial

13 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A three year comparative multicenter study of auranofin (AF) and gold sodium thiomalate (GST) in the treatment of rheumatoid arthritis (RA)

13 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis

13 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis

13 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study

13 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study

13 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects?

13 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis

13 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis

13 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

The cost effectiveness of auranofin: results of a randomized clinical trial

13 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires

13 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study

13 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis

13 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

13 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis

13 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Toward an understanding of patient outcome measurement

13 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Which traditional measures should be used in rheumatoid arthritis clinical trials?

13 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

What are the 'best' measurements for monitoring patients during short-term second-line therapy?

13 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Efficacy of tests used to monitor rheumatoid arthritis

13 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Critical review of clinical assessment techniques for rheumatoid arthritis trials: new developments

13 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

What should we hope to achieve when treating rheumatoid arthritis?

13 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Preference for endpoint measures in clinical trials: results of structured workshops

13 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

A COMPARISON OF THE ABILITY OF 28 ARTICULAR INDICES TO DETECT AN INDUCED FLARE OF JOINT INFLAMMATION IN RHEUMATOID ARTHRITIS

13 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response

13 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/0049-0172(92)90022-6

13 October 2022

Identifiers

1 reference

12 August 2017

1 reference